Treatment Trials
Below is a listing by cancer type of the current treatment clinical trials for cancer offered through the Genesis Cancer Care Institute and Iowa Cancer Specialists. See clinical trials offered by Hematology-Oncology Associates of the Quad-Cities, PC.
Each trial below is linked to a complete description provided by the National Cancer Institute. You may then choose a patient version or health professional version to read and print out as you wish. If you need assistance with this process, contact us. You may search for other clinical trials through the following links: National Cancer Institute Clinical Trial Search; Emerging Med; Trial Check; or Center Watch.
Breast Cancer
NSABP B-39: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs Partial Breast Irradiation (PBI) for Women With Stage 0, I or II Breast Cancer (Partial Closure)
NSABP B-41
(Industry): Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered With Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
NSABP B-44
(Industry): The BETH trial--Bevacizumab With Trastuzumab Adjuvant Therapy in HER2 (+) Breast Cancer
NSABP B-46
(Industry): A Phase III Clinical Trial Comparing the Combination of TC Alone and to TAC for Women with Node Positive or High-Risk Node Negative, HER2-Negative Breast Cancer
SWOG S0221: Phase III Trial of Continuous Schedule AC + G vs Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer
SWOG S0622: Phase II Studies of Two Different Schedules of Dasatinib in Bone Metastasis Predominant Metastatic Breast Cancer
ECOG E5103: Double-Blind Phase III Trial of Doxorubicin/Cyclophosphamide Followed by Paclitaxel With Bevacizumab or Placebo in Patients With Lymph Node (+) and High Risk Lymph Node (-) Breast Cancer
CALGB 40101: Cyclophosphamide and Doxorubicin (CA) (4 vs 6 cycles) vs Paclitaxel (4 vs 6 cycles) as Adjuvant Therapy for Women with Node Negative Breast Cancer: A 2X2 Factorial Randomized Study
CALGB 40302: Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: A Randomized Double Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
CALGB 40502: A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone Combined With Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
CALGB 70301: Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Node-Negative Breast Cancer (Companion Study to CTSU 40101)
IBCSG 24-02: Suppression of Ovarian Function Trial (SOFT)
NCCTG N0733: Phase II Trial of Capecitabine and Lapatinib With or Without IMC-A12 in Patients With HER2 (+) Breast Cancer Previously Treated With Trastuzumab and an Anthracycline and/or a Taxane
ECOG PACCT-1 (Program for the Assessment of Clinical Cancer Tests): Trial assigning Individualized Options for Treatment
back to top
Carcinoid Tumor
SWOG S0518: Phase III Prospective Randomized Comparison of Depot Octreotide + Interferon Alpha vs Depot Octreotide + Bevacizumab in Advanced, Poor Prognosis Carcinoid Patients
back to top
Gastro-Intestinal (Colon Cancer; Rectal Cancer; Gastrointestional Stromal Tumor)
ECOG E5202: Randomized Phase III Study Comparing 5-FU, Leucovorin and OXAL vs 5-FU, Leucovorin, OXAL and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
CALGB 80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin With Bevacizumab or Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum
NSABP R-04: Treatment With Two Chemotherapy Drugs Combined With Radiation Therapy for Patients With Rectal Cancer
back to top
Genito-Urinary (Prostate; Kidney)
MDA 3410: A Prospective Randomized Phase III Trial Comparing Consolidation Therapy With or Without Strontium-89 (SR 89) Following Induction Chemotherapy in Androgen-Independent Prostate Cancer
CALGB 90203
: Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy vs Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer
ECOG 2804
: The BeST Trial, A Randomized Phase II Study of VEGF, RAF kinase and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma
ECOG 2805: Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib vs Sorafenib vs Placebo in Patients With Resected Renal Cell Cancer
SWOG S0421: Phase III Study of Docetaxel and Atrasentan vs Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer
back to top
GYNECOLOGY (Endometrial; Ovarian Epithelial)
back to top
Head & Neck
back to top
Leukemia (Acute Myeloid (AML) Adult; Chronic Lymphocytic (CLL))
SWOG S9910: Leukemia Centralized Reference Lab and Tissue Repositories-Consent to Perform Cellular and Molecular Studies in Leukemia Patients
back to top
Lung (Non-Small Cell)
AC01L08 (Industry): A Multi-Center Randomized Phase 2b Study of Cetuximab (Erbitux) in Combination With Platinum-Based Chemotherapy as First-Line Treatment of Patients With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)
SWOG S9925: Lung Cancer Specimen Repository Protocol, Ancillary
SWOG S0424: Molecular Epidemiology Case-Series of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men (Female and male smoker strata closed- 7/15/07)
SWOG S0720: Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
ECOG 1505: Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (> 4 cm)-IIIA Non-Small Cell Lung Cancer
back to top
Lymphoma
SWOG 8819: Central Lymphoma Repository Tissue Procurement Protocol
SWOG 9245: Central Lymphoma Repository Tissue Procurement Protocol for Relapse or Recurrent Disease
back to top
Melanoma
ECOG 1697: Phase III Randomized Study of Four Weeks High Dose IFN-2b in Stage T2B N0, T3A-B N0, T4A-B N0 and T1-4, N1A, 2A (microscopic) Melanoma
back to top
Miscellaneous
SWOG S0702: Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
CALGB 70604: Randomized, Phase III Study of Standard Dosing vs Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer
SWOG S0715: Randomized Placebo-Controlled Trial of Acetyl L-Carnitine for the Prevention of Taxane-Induced Neuropathy
back to top
Multiple Myeloma
SWOG S0309: Myeloma Specimen Repository Protocol, Ancillary
ECOG 1A06: An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide vs Melphalan, Prednisone and Lenalidomide in Newly Diagnosed Myeloma Patients Who Are Not Candidates for High-Dose Therapy
back to top
